시장보고서
상품코드
1663018

암 종양 프로파일링 시장 규모, 점유율, 성장 분석, 암 유형별, 바이오마커 유형별, 기술별, 방법별, 용도별, 지역별 - 산업 예측(2025-2032년)

Cancer Tumor Profiling Market Size, Share, and Growth Analysis, By Cancer type (Breast Cancer, Lung Cancer), By Biomarker type (Genomic Biomarker, Protein Biomarker), By Technology, By Technique, By Application, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 219 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 종양 프로파일링 세계 시장 규모는 2023년에 121억 달러로 평가되었습니다. 2024년 134억 4,000만 달러에서 2032년에는 312억 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 11.1%의 연평균 복합 성장률(CAGR)을 보일 전망입니다.

세계 암 진단 및 치료 시장은 암 유병률 증가와 종양 프로파일링에서 바이오마커의 사용 증가로 인해 강화되고 있습니다. 연구 자금 증가와 기술 발전은 암 및 종양 프로파일링 분야의 성장을 가속하고 있습니다. 또한, 개인 맞춤형 의료 및 현장 진단을 향한 추세는 향후 몇 년동안 시장 진출기업들에게 큰 비즈니스 기회를 창출할 것으로 예상되며, 코로나19 팬데믹은 초기에는 암 검사 및 진단에 혼란을 가져왔지만, 전체 시장은 회복력을 유지했습니다. 예측 기간 동안 유전체학, 단백질체학, 후성유전학, 대사체학을 포함한 암/종양 프로파일링 분야가 성장할 것으로 예상되며, 특히 유전체학은 19.7%의 연평균 복합 성장률(CAGR)로 가장 높은 성장률을 나타낼 것으로 예상되며, 암의 회복력과 진행과 관련된 유전자 이상 규명에서 혁신을 촉진할 것으로 예상됩니다. 혁신을 촉진할 것입니다.

목차

서론

  • 조사 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차와 1차 데이터 방법
  • 시장 규모 예측
  • 시장 전제조건과 제한

주요 요약

  • 세계 시장 전망
  • 공급과 수요 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter의 Five Forces 분석

주요 시장 인사이트

  • 중요 성공 요인
  • 경쟁 정도
  • 주요 투자 기회
  • 시장 생태계
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

암 종양 프로파일링 시장 규모 : 암 유형별

  • 시장 개요
  • 유방암
  • 폐암
  • 대장암
  • 전립선암
  • 흑색종암
  • 기타 암

암 종양 프로파일링 시장 규모 : 바이오마커 유형별

  • 시장 개요
  • 유전체 바이오마커
  • 단백질 바이오마커

암 종양 프로파일링 시장 규모 : 기술별

  • 시장 개요
  • 면역측정
  • 차세대 시퀀싱
  • 중합효소 연쇄반응
  • 질량분석
  • In-Situ Hybridization
  • 마이크로어레이
  • 기타

암 종양 프로파일링 시장 규모 : 방법별

  • 시장 개요
  • 유전체학
  • 단백질체학
  • 대사체학
  • 에피제네틱스

암 종양 프로파일링 시장 규모 : 용도별

  • 시장 개요
  • 조사
  • 바이오마커 탐색
  • 맞춤형 의료
  • 임상 응용
  • 진단
  • 예측
  • 스크리닝
  • 치료 및 모니터링

암 종양 프로파일링 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 주요 5개사 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 최근 시장 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • 기업 상세
    • 제품 포트폴리오 분석
    • 기업 부문별 점유율 분석
    • 전년대비 매출 비교(2022-2024년)

주요 기업 개요

  • Illumina, Inc.(USA)
  • QIAGEN N.V.(Netherlands)
  • NeoGenomics, Inc.(USA)
  • Thermo Fisher Scientific(USA)
  • Roche Diagnostics(Switzerland)
  • Guardant Health, Inc.(USA)
  • Foundation Medicine, Inc.(USA)
  • Sysmex Corporation(Japan)
  • Becton, Dickinson and Company(BD)(USA)
  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Merck & Co., Inc.(USA)
  • Pfizer Inc.(USA)
  • Novartis AG(Switzerland)
  • AstraZeneca(UK)
  • Bristol-Myers Squibb Company(USA)
  • Johnson & Johnson(USA)
  • Danaher Corporation(USA)
  • Abbott Laboratories(USA)

결론과 제안

LSH 25.03.31

Global Cancer Tumor Profiling Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.44 billion in 2024 to USD 31.2 billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The global cancer detection and treatment market is bolstered by the rising prevalence of cancer and the increasing utilization of biomarkers in tumor profiling. Enhanced research funding and technological advancements are fueling growth in the cancer and tumor profiling sectors. Furthermore, the trend towards personalized medicine and point-of-care diagnostics is anticipated to create substantial opportunities for market participants in the coming years. While the COVID-19 pandemic initially disrupted cancer testing and diagnosis, the overall market remained resilient. During the forecast period, cancer/tumor profiling segments encompassing genomics, proteomics, epigenetics, and metabolomics are expected to thrive, with genomics projected to achieve the highest CAGR of 19.7%, driving innovations in understanding gene abnormalities connected to cancer resilience and progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Tumor Profiling market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Tumor Profiling Market Segments Analysis

Global Cancer Tumor Profiling Market is segmented by Cancer type, Biomarker type, Technology, Technique, Application and region. Based on Cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer. Based on Biomarker type, the market is segmented into Genomic Biomarker and Protein Biomarker. Based on Technology, the market is segmented into Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays and Others. Based on Technique, the market is segmented into Genomics, Proteomics, Metabolomics and Epigenetics. Based on Application, the market is segmented into Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening and Treatment and Monitoring. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Tumor Profiling Market

The rise in cancer cases significantly drives the growth of the global cancer tumor profiling market. This increase in cancer prevalence is influenced by several factors, including an aging population, population growth, and shifts in the incidence of various cancer-causing elements. As cancer remains a complex and pervasive disease with various underlying causes, the growing burden necessitates advanced profiling techniques to enhance diagnosis, treatment, and patient outcomes. The urgent need for tailored therapeutic approaches arises from this complex landscape, solidifying the importance of cancer tumor profiling in addressing the ongoing challenges posed by the escalating incidence of cancer worldwide.

Restraints in the Global Cancer Tumor Profiling Market

Challenges related to technical issues in sample collection and storage present significant obstacles to the growth of the global cancer tumor profiling market. While personalized medicine is rapidly evolving and transforming disease identification, classification, and treatment in healthcare, these advancements are hampered by inconsistent sample management processes. As this more tailored approach to treatment becomes integrated into standard clinical practices, its impact on oncology is undeniable. However, the risks associated with sample handling and storage could impede the progress and acceptance of these innovations, ultimately affecting the overall development of the cancer tumor profiling sector.

Market Trends of the Global Cancer Tumor Profiling Market

The Global Cancer Tumor Profiling market is witnessing a significant trend driven by the integration of omics data and advancements in liquid biopsy technologies, projected to exhibit the highest CAGR during the forecast period. This shift aligns with the rising prominence of personalized medicine, transforming disease diagnosis, classification, and treatment. As tailored therapies become a standard in clinical practice, particularly within oncology, the market is evolving to accommodate innovative diagnostic tools and targeted treatment approaches. The convergence of advanced analytics and molecular profiling is revolutionizing cancer care, fostering early detection and improved patient outcomes across the globe.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Cancer Tumor Profiling Market Size by Cancer type & CAGR (2025-2032)

  • Market Overview
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Other Cancer

Global Cancer Tumor Profiling Market Size by Biomarker type & CAGR (2025-2032)

  • Market Overview
  • Genomic Biomarker
  • Protein Biomarker

Global Cancer Tumor Profiling Market Size by Technology & CAGR (2025-2032)

  • Market Overview
  • Immunoassays
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Mass Spectrometry
  • In-Situ Hybridization
  • Microarrays
  • Others

Global Cancer Tumor Profiling Market Size by Technique & CAGR (2025-2032)

  • Market Overview
  • Genomics
  • Proteomics
  • Metabolomics
  • Epigenetics

Global Cancer Tumor Profiling Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Research
  • Biomarker Discovery
  • Personalized Medicine
  • Clinical Application
  • Diagnostics
  • Prognostics
  • Screening
  • Treatment and Monitoring

Global Cancer Tumor Profiling Market Size & CAGR (2025-2032)

  • North America (Cancer type, Biomarker type, Technology, Technique, Application)
    • US
    • Canada
  • Europe (Cancer type, Biomarker type, Technology, Technique, Application)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Cancer type, Biomarker type, Technology, Technique, Application)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Cancer type, Biomarker type, Technology, Technique, Application)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Cancer type, Biomarker type, Technology, Technique, Application)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Illumina, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN N.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NeoGenomics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Diagnostics (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Guardant Health, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Foundation Medicine, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sysmex Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson and Company (BD) (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Danaher Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제